Navigation Links
Statins Lower Blood Marker for Prostate Cancer
Date:10/30/2008

But it's not clear if the cholesterol-lowering drugs protect against the disease

THURSDAY, Oct. 30 (HealthDay News) -- A new study shows that men who take cholesterol-lowering drugs called statins have lower blood levels of prostate-specific antigen (PSA), a biomarker for prostate cancer risk.

That drop in PSA levels doesn't necessarily mean the drugs protect against disease however, researchers say.

But it's possible that statins may offer some protection against the disease, said Dr. Robert Hamilton, one author of the report in the Oct. 28 issue of the Journal of the National Cancer Institute. He worked on the study while a research fellow at Duke University; he is now a urology resident at the University of Toronto.

"The reduction in PSA was in proportion to the dose of statins that were taken and to the reduction of cholesterol levels," Hamilton said, indicators of a possible protective effect.

The study was done because of "encouraging recent data" from four previous studies showing an association between statin therapy and reduced PSA levels, and a reduced risk of advanced prostate cancer, he said.

The study followed 1,214 men who were prescribed statins between 1990 and 2006 at the Durham Veterans Affairs Medical Center in North Carolina. PSA levels declined by about 4 percent after statin therapy was started, with the greatest reductions seen in men who took the largest doses of statins and had the largest drops in blood cholesterol levels.

The results parallel those of a study reported in 2005 by a group led by Dr. Dov Kadmon, a professor of urology at the Baylor College of Medicine.

"Our study was the first to show a relationship between PSA levels and either lowering of cholesterol or treatment with statins," Kadmon said. "We could not distinguish whether lowering cholesterol or statin treatment was responsible, because our study was not designed to show that."

Kadmon and his colleagues followed 100 commercial airline pilots, a group chosen because federal regulations require them to have regular medical exams. The five-year study showed that "pilots on statins had a 46 percent decrease in PSA levels, while the control group had a slow increase in PSA levels, which are known to go up with age," Kadmon said.

The study was too small and too short to tell whether statins might protect against prostate cancer, Kadmon said. "But we know that when men have higher PSA levels, there is a higher chance that they will be diagnosed with prostate cancer," he said. "It is worth looking into by conducting a larger study."

"There is no question that a large, randomized, controlled trial with a long follow-up would most likely answer the question," Hamilton said. "It would be an expensive, huge undertaking."

Why statins affect PSA levels is unclear, Hamilton said. "We have some idea of how statins interact with prostate biology," he said. "But we don't know the exact mechanism by which statins influence PSA."

The anti-inflammatory action of statins is one of the possible mechanisms, Hamilton said. "We need to learn more about prostate cancer and statins before we launch a huge study," he added.

More information

Statins and other drugs that lower cholesterol are described by the American Heart Association.



SOURCES: Robert Hamilton, M.D., urology resident, University of Toronto; Dov Kadmon, M.D., professor, urology, Baylor College of Medicine, Houston; Oct. 28, 2008, Journal of the National Cancer Institute


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Stopping Statins After Stroke Doubles Death Risk
2. Research to shed new light on how statins benefit heart patients
3. Statins reduce loss of function, keeping old lungs young - even in smokers
4. Better Prostate Cancer Survival for Men Taking Statins
5. Statins After Bypass Lower Stroke Risk
6. Latest Study Says Statins Dont Slow Alzheimers
7. New Gene-Based Therapy an Alternative to Vytorin and Statins in Heart Disease Prevention and Treatment
8. Tendon complications, though rare, linked to statins
9. Cholesterol-Lowering Statins Tied to Tendon Woes
10. Women are treated less frequently than men with statins, aspirin and beta-blockers
11. iGuard.org Presents New Data on Statins at FDA Workshop Demonstrating How Patient-Reported Information Can Enhance Drug Safety Knowledge
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... KICKICO ... a whitepaper that pledges to solve many catastrophic issues within funding campaigns. KICKICO ... , The typical notion of crowdfunding - the raising of funds through the power ...
(Date:6/25/2017)... , ... June 24, 2017 , ... Create a feel-good lyric music video in Final ... and sound in the timeline and write in the lyrics to any song. ProLyric flies ... out. Each line of the text can be added modularly for optimal control. ProLyric makes ...
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology: